盧夫特韋

盧夫特韋
法律規範狀態
法律規範	美：Investigational drug;
識別資訊
	IUPAC命名法 [(3S)-3-[(2S)-2-[(4-methoxy-1H-indol-2-yl)formamido]-4-methylpentanamido]-2-oxo-4-[(3S)-2-oxopyrrolidin-3-yl]butoxy]phosphonic acid; ;
CAS號	2468015-78-1
PubChem CID	154699467;
DrugBank	DB16514;
UNII	XJ51YOB1SC;
KEGG	D12172;
ChEBI	CHEBI:173073;
CompTox Dashboard（英語：CompTox Chemicals Dashboard） (EPA)	DTXSID501337108 ;
化學資訊
化學式	C24H33N4O9P
摩爾質量	552.52 g·mol−1
3D模型（JSmol（英語：JSmol））	交互式圖像;
	SMILES CC(C)C[C@@H](C(=O)N[C@@H](C[C@@H]1CCNC1=O)C(=O)COP(=O)(O)O)NC(=O)C2=CC3=C(N2)C=CC=C3OC;
	InChI InChI=1S/C24H33N4O9P/c1-13(2)9-18(28-24(32)19-11-15-16(26-19)5-4-6-21(15)36-3)23(31)27-17(10-14-7-8-25-22(14)30)20(29)12-37-38(33,34)35/h4-6,11,13-14,17-18,26H,7-10,12H2,1-3H3,(H,25,30)(H,27,31)(H,28,32)(H2,33,34,35)/t14-,17-,18-/m0/s1; Key:FQKALOFOWPDTED-WBAXXEDZSA-N;

盧夫特韋（英語：Lufotrelvir、PF-07304814）是輝瑞公司開發的一種抗病毒藥物，可作為3CL 蛋白酶抑制劑。^[1]它是一種前體藥物，其磷酸基團在體內被裂解以產生活性劑PF-00835231。^[2]盧夫特韋正在用於治療COVID-19的人體臨床試驗中，並顯示出對COVID-19的良好活性，包括幾種變異株，但與相關藥物奈瑪特韋不同，它沒有口服活性，必須通過靜脈注射給藥，因此一直總體而言，臨床開發中不太受歡迎的候選者。^[3]^[4]^[5]

參見

參考文獻

^ Hoffman RL, Kania RS, Brothers MA, Davies JF, Ferre RA, Gajiwala KS, et al. Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19. Journal of Medicinal Chemistry. November 2020, 63 (21): 12725–12747. PMC 7571312  . PMID 33054210. doi:10.1021/acs.jmedchem.0c01063.
^ Boras, Britton; Jones, Rhys M.; Anson, Brandon J.; Arenson, Dan; Aschenbrenner, Lisa; Bakowski, Malina A.; Beutler, Nathan; Binder, Joseph; Chen, Emily; Eng, Heather; Hammond, Holly. Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19. Nature Communications. 2021-10-18, 12 (1): 6055. Bibcode:2021NatCo..12.6055B. ISSN 2041-1723. PMC 8523698  . PMID 34663813. doi:10.1038/s41467-021-26239-2 （英語）.
^ de Vries M, Mohamed AS, Prescott RA, Valero-Jimenez AM, Desvignes L, O'Connor R, et al. A comparative analysis of SARS-CoV-2 antivirals characterizes 3CL^pro inhibitor PF-00835231 as a potential new treatment for COVID-19. Journal of Virology. February 2021, 95 (10). PMC 8139662  . PMID 33622961. doi:10.1128/JVI.01819-20.
^ Baig MH, Sharma T, Ahmad I, Abohashrh M, Alam MM, Dong JJ. Is PF-00835231 a Pan-SARS-CoV-2 Mpro Inhibitor? A Comparative Study. Molecules. March 2021, 26 (6): 1678. PMC 8002701  . PMID 33802860. doi:10.3390/molecules26061678  .
^ Vandyck K, Deval J. Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection. Current Opinion in Virology. August 2021, 49: 36–40. PMC 8075814  . PMID 34029993. doi:10.1016/j.coviro.2021.04.006.

[1] Hoffman RL, Kania RS, Brothers MA, Davies JF, Ferre RA, Gajiwala KS, et al. Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19. Journal of Medicinal Chemistry. November 2020, 63 (21): 12725–12747. PMC 7571312  . PMID 33054210. doi:10.1021/acs.jmedchem.0c01063.

[2] Boras, Britton; Jones, Rhys M.; Anson, Brandon J.; Arenson, Dan; Aschenbrenner, Lisa; Bakowski, Malina A.; Beutler, Nathan; Binder, Joseph; Chen, Emily; Eng, Heather; Hammond, Holly. Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19. Nature Communications. 2021-10-18, 12 (1): 6055. Bibcode:2021NatCo..12.6055B. ISSN 2041-1723. PMC 8523698  . PMID 34663813. doi:10.1038/s41467-021-26239-2 （英語）.

[3] Vries M, Mohamed AS, Prescott RA, Valero-Jimenez AM, Desvignes L, O'Connor R, et al. A comparative analysis of SARS-CoV-2 antivirals characterizes 3CL^pro inhibitor PF-00835231 as a potential new treatment for COVID-19. Journal of Virology. February 2021, 95 (10). PMC 8139662  . PMID 33622961. doi:10.1128/JVI.01819-20.

[4] Baig MH, Sharma T, Ahmad I, Abohashrh M, Alam MM, Dong JJ. Is PF-00835231 a Pan-SARS-CoV-2 Mpro Inhibitor? A Comparative Study. Molecules. March 2021, 26 (6): 1678. PMC 8002701  . PMID 33802860. doi:10.3390/molecules26061678  .

[5] Vandyck K, Deval J. Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection. Current Opinion in Virology. August 2021, 49: 36–40. PMC 8075814  . PMID 34029993. doi:10.1016/j.coviro.2021.04.006.

[1]

[2]

[3]

[4]

[5]

法律規範狀態

法律規範	美：Investigational drug
識別資訊
IUPAC命名法 [(3S)-3-[(2S)-2-[(4-methoxy-1H-indol-2-yl)formamido]-4-methylpentanamido]-2-oxo-4-[(3S)-2-oxopyrrolidin-3-yl]butoxy]phosphonic acid
CAS號	2468015-78-1
PubChem CID	154699467
DrugBank	DB16514
UNII	XJ51YOB1SC
KEGG	D12172
ChEBI	CHEBI:173073
CompTox Dashboard（英語：CompTox Chemicals Dashboard） (EPA)	DTXSID501337108
化學資訊
化學式	C₂₄H₃₃N₄O₉P
摩爾質量	552.52 g·mol⁻¹
3D模型（JSmol（英語：JSmol））	交互式圖像
SMILES CC(C)C[C@@H](C(=O)N[C@@H](C[C@@H]1CCNC1=O)C(=O)COP(=O)(O)O)NC(=O)C2=CC3=C(N2)C=CC=C3OC
InChI InChI=1S/C24H33N4O9P/c1-13(2)9-18(28-24(32)19-11-15-16(26-19)5-4-6-21(15)36-3)23(31)27-17(10-14-7-8-25-22(14)30)20(29)12-37-38(33,34)35/h4-6,11,13-14,17-18,26H,7-10,12H2,1-3H3,(H,25,30)(H,27,31)(H,28,32)(H2,33,34,35)/t14-,17-,18-/m0/s1 Key:FQKALOFOWPDTED-WBAXXEDZSA-N